A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
Clinical trial NCT07406282 · RECRUITING
Trial details
- NCT number
- NCT07406282
- Sponsor
- Bayer
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-07-22
- Primary completion
- 2026-09-30
- Enrollment
- 1400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.